New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated ...

TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis (Angiogenesis, ...

1) the active drug substance Axitinib, which used to belong to Pfizer, is an FDA-approved, oral, potent VEGFR inhibitor. So ...

Regeneron beat Q4 earnings and sales estimates as Dupixent gains offset weaker Eylea sales. The drugmaker also outlined 2026 ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Regeneron Pharmaceuticals, Inc. is a better investment based on ...

Enzeevum, a biosimilar to Eylea, is approved in Canada for multiple retinal conditions, expanding treatment options for ophthalmologists. Biosimilars may offer cost-effective alternatives, potentially ...

Non-GAAP earnings slipped 5% to $11.44 per share but still came in ahead of analysts’ forecasts of $10.74. ・Sales of the ...

Sandoz, the global leader in affordable medicines, today announced the launch of Enzeevu® (aflibercept) in Canada, its first ophthalmology biosimilar, expanding access to affordable treatment options ...

Analysts said near-term catalysts remain limited, with Phase 3 melanoma data as the next key event to watch.

Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar ...

In addition to demonstrating that the vision gains and anatomic achievements or improvements with EYLEA HD over two years ...

Growth is driven by the rapidly aging global population, rising prevalence of chronic diseases such as diabetes, and ...